Cellectar Biosciences, Inc. — Director's Dealing 2025

Dec 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2025-12-12

Reporting Person: NEIS JOHN (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-12	Common Stock	S	198	$3.6969	Disposed	10	Indirect

Footnotes

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.631 to $3.70, inclusive. The reporting person has provided to the Issuer, and undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote (1) to this Form 4.

F2: This number has been adjusted for (i) the one-for-thirty (1:30) reverse stock split effected by the Issuer on June 24, 2025, (ii) the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022, and (iii) the one-for-ten (1:10) reverse stock split effected by the Issuer on July 16, 2018.

F3: These securities are held by Advantage Capital Wisconsin Partners I, Limited Partnership. Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of Venture Investors LLC are made collectively by five managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest herein.